Vascular endothelial growth factor receptors (VEGFRs), Raf kinase, Platelet-derived growth factor receptor beta (PDGFRβ), and Fibroblast growth factor receptor 1 (FGFR1) (VEGFR, RAF, PDGFRβ, FGFR1)

These targets are central molecules in key signaling pathways and include VEGFRs (which regulate angiogenesis and lymphangiogenesis, critical in tumor growth and metastasis), Raf kinase (a major component of the RAS/RAF/MEK/ERK pathway central to cell proliferation and survival), PDGFRβ (which drives cell proliferation, migration, and angiogenesis in normal and malignant tissues), and FGFR1 (modulates cell growth, differentiation, and angiogenesis). Aberrant activation or overexpression is implicated in oncogenesis, tumor maintenance, therapeutic resistance, and vascular pathologies. Drugs targeting these molecules are mainly kinase inhibitors, frequently used in cancer therapy, particularly for tumors driven by abnormal angiogenesis or growth factor signaling. Note: Presenting them together as a single target is not standard scientific practice; each name refers to a distinct protein. For proper structured information, individual records should be generated per target, rather than grouping as above.

Other names

Vascular endothelial growth factor receptor familyFLT-1 for VEGFR1KDR for VEGFR2c-RafRaf-1BRAFPDGF receptor betaCD140bFGF receptor 1

Inhibition of kinase activity via ATP-competitive binding—blocks phosphorylation, halts downstream signaling and cellular responses. Anti-angiogenesis: blocking blood vessel formation via VEGFR, FGFR, PDGFRβ inhibition.